Amneal Biosciences

Alymsys

Manufacturer:

Amneal Biosciences

Alymsys HCPCS:

C9142

HCPCS Code Descriptor:

Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

Category:

C Code

Alymsys NDCs:

No actively aligned NDCs found

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Alymsys:

Alymsys is an Oncology Biosimilar drug manufactured by Amneal Biosciences and administered via the Intravenous route of administration. The C Code: C9142 is aligned to the drug Alymsys.

ACCESS PRICING AND MORE BY REGISTERING

C9142 Added Date:

October 1, 2022

C9142 Effective Date:

January 1, 2023

C9142 Termination Date:

December 31, 2022

We have not yet identified a manufacturer source of Alymsys billing and coding information.
Alymsys patient assistance information can be found through The Amneal Patient Assistance Program at the URL: https://www.amneal.com/about/responsibility/patient-assistance-programs/
Alymsys prescribing information can be found at the link below:
Information regarding Alymsys’s side effects can be found at MedlinePlus